Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Overview of attention for article published in New England Journal of Medicine, March 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news: 24 news outlets
blogs: 2 blogs
policy: 2 policy sources
twitter: 153 X users
patent: 14 patents
facebook: 1 Facebook page

wikipedia: 1 Wikipedia page
reddit: 1 Redditor
f1000: 1 research highlight platform
guideline: 7 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 688 Mendeley

So far, Altmetric has seen 39 news stories from 24 outlets.

Pirtobrutinib Combo Boosts PFS in Previously Treated CLL/SLL

Cancer Network, 03 Aug 2026

Fixed-duration pirtobrutinib (Jaypirca) plus venetoclax (Venclexta) and rituximab (Rituxan; PVR) significantly improved…

Pirtobrutinib Combo Boosts PFS in Previously Treated CLL/SLL

UBM Medica, 03 Aug 2026

Pirtobrutinib plus venetoclax/rituximab reduced the risk of progression or death by 45% among those with CLL in the phase 3…

Real-World Data Support Safety, Efficacy of Venetoclax for CLL

AJMC, 29 Aug 2025

Venetoclax (Venclexta; Abbvie and Genentech) therapy in patients with chronic lymphocytic leukemia (CLL) showed similar…

Long-Term Data Support Venetoclax Plus Rituximab in Relapsed/Refractory CLL

OncLive, 18 Jun 2025

Venetoclax plus rituximab significantly improves PFS and OS in relapsed/refractory CLL compared to bendamustine plus rituximab.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 35 additional news stories.